Sign in

    Rohan Mathur • Oppenheimer & Co. Inc.

    Rohan Mathur's questions to Catalyst Pharmaceuticals Inc (CPRX) leadership

    Rohan Mathur's questions to Catalyst Pharmaceuticals Inc (CPRX) leadership • Q1 2025

    Question

    Rohan Mathur of Oppenheimer asked which aspects of AGAMREE's clinical profile, as evaluated in the SUMMIT study, are expected to most resonate with prescribers. He also followed up by asking how these benefits would be quantified in the study.

    Answer

    Chief Medical Officer Gary Ingenito responded, highlighting that the key differentiating findings from the SUMMIT study are expected to be related to bone health and cardiac effects. He specified that the study will quantify these benefits by measuring fracture rates, bone age, bone density, and the prevention of cardiomyopathy.

    Ask Fintool Equity Research AI

    Rohan Mathur's questions to Crinetics Pharmaceuticals Inc (CRNX) leadership

    Rohan Mathur's questions to Crinetics Pharmaceuticals Inc (CRNX) leadership • Q4 2024

    Question

    Rohan Mathur asked about the commercial synergies for paltusotine between the acromegaly and carcinoid syndrome indications, given potential overlapping call points.

    Answer

    CEO R. Struthers identified several areas of synergy. He noted the geographic overlap of pituitary and oncology centers of excellence, the confidence that safety data in acromegaly will provide for the carcinoid indication, and the significant prescriber overlap between the two conditions in many European countries, which creates direct efficiencies.

    Ask Fintool Equity Research AI

    Rohan Mathur's questions to Cytokinetics Inc (CYTK) leadership

    Rohan Mathur's questions to Cytokinetics Inc (CYTK) leadership • Q3 2024

    Question

    Rohan Mathur from Oppenheimer asked how the ongoing launch of a competitor's cardiac myosin inhibitor might help catalyze market awareness and payer coverage, benefiting aficamten's potential launch.

    Answer

    Andrew Callos, EVP and CCO, explained that as a second-to-market agent, aficamten benefits from the incumbent's efforts in building broad disease awareness through HCP and patient campaigns. This allows Cytokinetics to focus its resources more on educating physicians about aficamten's specific profile and points of differentiation, which should aid uptake in an already primed market.

    Ask Fintool Equity Research AI